Research and development daily, the first domestic qural-beadmed biosimilar drug will soon be approved

Xi'an Jansen releases 4-year clinical data on Tremfya psoriasis Skin removal rate maintains high levels; Shadon Bio 1 new drug treatment of multiple myeloma Iii clinical success; authorization for emergency use of chloroquine/hydroxychloroquine treatment COVID-19 is revoked..We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information referenceon15, Xi'an Jansen Pharmaceuticals released the latest data from VOYAGE 2, a long-term clinical trial of Tremfya for patients with plaque yandruff diseaseThe results showed that Tremfya showed good consistency and high skin removal rates at two time baselines of 100 weeks and 204 weeks (four years) as a first-line treatmentFrench biopharmaceutical company Inventiva recently announced that it has tested positive results from the PPAR agonisant lanifibranor's treatment of non-alcoholic fatty hepatitis (NASH) IIb NATIVE15th, Hait Biologicals issued a notice that its joint venture company Shadong Bio independently developed recombinant variable tumor necrosis factor-related apoptosis-induced ligands for the treatment of recurrent or refractive patients with multiple myeloma Phase III clinical success15th, The Company of Lepu BioHoldings subsidiary Taizhou Hanzhong Pharmaceuticals initiated Phase III clinical studies in PD-1, in conjunction with the second-line treatment of advanced gastric cancer phase III clinical studiesRecently, the Fda approved ViiV Healthcare's Tivicay PD's first dispersive tablet formulation, which can be used in combination with other antiretroviral drugs to treat children infected with hiv-1 immunodeficiency virus (HIV-1) who is at least 4 weeks old, weighing at least 3 kg, previously untreated or treated but not treated with integrated enzyme chain transferinhibitor inhibitors15, the FDA announced the withdrawal of chloroquine/hydroxychloroquine treatment COVID-19 emergency use authorizationThe revocation request is based on new information, including clinical trial data, that the drug may not be effective for the treatment of COVID-19, and that the potential benefits of the drug for such use do not exceed its known and potential risksrecently, Watson Bio announced that its holding subsidiary Shanghai Zerun Bio submitted a recombinant HPV double-price (type 16/18) vaccine (yeast) (divalent HPV vaccine) on the market application was accepted by the State Drug Administration15, Jazz Pharmaceuticals/PharmaMar announced that the FDA has accelerated the approval of Zepzelca for the treatment of metastatic small cell lung cancer, which progresses after chemotherapy for platinum drugs16, Hengrui PD-1 monoanti-carellizumab new adaptation of the listing application in NMPA status changed to "in approval", which means that Carilli Zhu sing-iso-singof 2 new indications (single-drug second-line treatment of advanced esophageal scale cancer, combined peme qurandin and karpedi first-line treatment of advanced or metastatic non-small cell lung cancer) was approved in the hope,000-person pharmaceutical company announced today that its controlling subsidiary Puracap Pharmaceutical LLC has recently received the FDA's approval number for omega-3-ethyl ethyl acid softgelstoday, the U.SFDA announced the approval of the first game-based digital therapy device to improve attention function in children with attention deficit hyperactivity disorder The game-based device, called EndeavorRx, was developed by Akili Interactive 16th, Sansheng Guojian 2 new drug "qutozhu zuma" in the domestic listing application approval status changed to "in approval", after three rounds of supplementary information, clinical on-site verification and production site inspection, is expected to be approved for listing, becoming the first domestic querupel zuma biological similar drug recently, according to CDE public information, Zhengda Tianqing today submitted the Adamu sing-it-againstre injection application, and TKI inhibitor Anrotinib 3 clinical trial applications today, CDE publicinformation, Huahai Pharmaceuticalsubsidiary subsidiary Huabo Bio and Huaotai Biological jointly declared the HB0017 injection to obtain a clinical implied license, indications for moderate to severe plaque-like psoriasis , Dongsun announced that its controlling subsidiary, Dongsun Pharmaceuticals, "Recombinant Human Insulin Injection" was approved by the State Drug Administration for listing, becoming the first biological products drug approved for listing of Dongsun Pharmaceuticals.